NIFK Inhibitors
Chemical inhibitors of NIFK include a range of compounds that target different aspects of cellular function to achieve inhibition. Staurosporine, a well-known protein kinase inhibitor, can disrupt the function of NIFK by reducing the phosphorylation levels of proteins that NIFK interacts with. Given that NIFK's binding to phosphorylated substrates is a critical aspect of its function, staurosporine's broad kinase inhibition can impair this interaction. Similarly, Alsterpaullone and Roscovitine, both cyclin-dependent kinase inhibitors, can inhibit NIFK by disrupting cell cycle progression, a process in which NIFK is involved. The inhibition of cyclin-dependent kinases leads to cell cycle arrest, which can indirectly inhibit the functions of NIFK related to cell division and proliferation.
Other inhibitors work by destabilizing the protein and preventing its proper function. For example, Geldanamycin binds to Hsp90, a chaperone important for the stability and activity of several proteins, including NIFK. The inhibition of Hsp90 can lead to the degradation of NIFK, thereby inhibiting its function. The inhibitors U0126 and PD98059 target the MEK/ERK pathway, which is involved in transmitting signals for cell growth and division. By inhibiting MEK1/2, these compounds can disrupt the signaling processes that NIFK might regulate, leading to functional inhibition. The PI3K inhibitors LY294002 and Wortmannin affect the AKT signaling pathway, which is crucial for a variety of cellular functions. The inhibition of PI3K can thus indirectly inhibit NIFK by disrupting these pathways. Mitoxantrone targets DNA replication by inhibiting type II topoisomerase, which is essential for cell proliferation, and since NIFK is associated with the cell cycle, mitoxantrone can indirectly inhibit NIFK's function in proliferative processes. Rapamycin, by inhibiting mTOR, suppresses cell growth and metabolism, both of which are processes where NIFK could be implicated, thus functionally inhibiting it. Lastly, Sunitinib, by inhibiting receptor tyrosine kinases, can impact the signaling pathways that involve NIFK, leading to its functional inhibition.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. NIFK is known to interact with proteins that are phosphorylated. By inhibiting kinase activity, Staurosporine can reduce the phosphorylation levels of these proteins, thereby inhibiting the function of NIFK in binding to phosphorylated substrates. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin binds to heat shock protein 90 (Hsp90), a molecular chaperone involved in the folding and stabilization of many proteins, including NIFK. Inhibition of Hsp90 can lead to the destabilization and degradation of NIFK, functionally inhibiting it. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor. NIFK is associated with cell cycle regulation. By inhibiting CDKs, Alsterpaullone can disrupt the cell cycle process and potentially inhibit NIFK functions that are related to cell cycle progression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream of extracellular signal-regulated kinases (ERK1/2). NIFK is involved in the regulation of mitotic progression, which can be influenced by the ERK pathway. Inhibiting MEK can therefore inhibit NIFK's function in this context. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. Since PI3K signaling affects a variety of cellular functions including those that NIFK might be involved in, such as cell growth and survival, inhibiting PI3K can disrupt these pathways and functionally inhibit NIFK. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, a central protein in regulating cell growth and metabolism. NIFK has been implicated in cell proliferation, and mTOR inhibition can suppress this process, leading to functional inhibition of NIFK activity in cell growth. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
Mitoxantrone is a type II topoisomerase inhibitor that disrupts DNA synthesis and repair. As NIFK is involved with the cell cycle and proliferative processes, inhibiting DNA replication can indirectly lead to functional inhibition of NIFK by preventing its associated activities. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a selective inhibitor of cyclin-dependent kinases (CDKs). By inhibiting CDKs, Roscovitine can interfere with cell cycle progression, which is essential for the function of NIFK in cell cycle regulation. This results in functional inhibition of NIFK. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which acts upstream of ERK in the MAPK pathway. NIFK is implicated in cell cycle regulation, which is influenced by the MAPK pathway. Inhibition of MEK, therefore, can result in functional inhibition of NIFK's role in cell cycle control. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which may interact with cellular processes involving NIFK. By inhibiting JNK, SP600125 can alter the cellular functions where NIFK is involved, leading to the functional inhibition of NIFK's activity. | ||||||